A blood-based signature of cerebrospinal fluid Aβ_1-42 status.

ABSTRACT: It is increasingly recognized that Alzheimer's disease (AD) exists before dementia is present and that shifts in amyloid beta occur long before clinical symptoms can be detected. Early detection of these molecular changes is a key aspect for the success of interventions aimed at slowing down rates of cognitive decline. Recent evidence indicates that of the two established methods for measuring amyloid, a decrease in cerebrospinal fluid (CSF) amyloid β_1-42 (Aβ_1-42) may be an earlier indicator of Alzheimer's disease risk than measures of amyloid obtained from Positron Emission Tomography (PET). However, CSF collection is highly invasive and expensive. In contrast, blood collection is routinely performed, minimally invasive and cheap. In this work, we develop a blood-bas

SUBMITTER: Goudey B 

PROVIDER: S-EPMC6409361 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature